血脂康对急性冠脉综合征患者CRP、TNF-α和血脂的影响

目的观察血脂康治疗急性冠脉综合征(ACS)的临床效果。方法将98例ACS患者随机分为血脂康治疗组和洛伐他汀治疗组各49例,两组在常规治疗的基础上,血脂康组在用血脂康口服,每次600mg,每天2次;洛伐他汀组晚间加服40mg洛伐他汀。另设49例正常对照组。观察患者治疗前后血清肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)和血脂水平的变化。结果两个治疗组治疗后CRP、TNF-α、总胆固醇(TC)、和低密度脂蛋白胆固醇(LDL-C)均明显下降(P均<0.01);与洛伐他汀组相比,血脂康组的高密度脂蛋白胆固醇(HDL-C)明显升高(P<0.01)。血脂康组无肝、肾功能异常。结论血脂康治疗ACS效果确切、安全,尤其适用于老年患者。

The effect of Xuezhikang on C - reactive protein, TNF- alpha and blood lipid in patients with acute coronary syndrome

Objective To summarize the clinical efficacy of Xuezhikang in treatment of patients with acute coronary syndrome (ACS).Methods 98 patients with ACS enrolled in this study were allocated to a Xuezhikang-treated group(n=49) and a Lovastatin-treated group(n=49).In addition to conventional treatment for these two groups,the Xuezhikang group received oral Xuezhikang 600mg,twice a day;the Lovastatin group received nocturnal oral Lovastatin 40mg.49 normal subjects were selected as the controls.The flutuation of serum tumor necrosis factor-alpha(TNF-alpha),C-reactive protein(CRP) and the blood lipid in patients with ACS were observed before and after treatment. Results In the two treated groups after treatment,decreased CRP,TNF-alpha and total cholesterol (TC) and low density lipoprotein-cholesterol(LDL-C) were found(P<0.01);in comparison to Lovastatin group,the high density lipoprotein-cholesterol(HDL-C) in Xuezhikang group elevated significantly(P<0.01).No toxicity reaction in Xuezhikang group. Conclusion The data suggested that the result is satisfactory and safe for Xuezhikang in treatment of ACS, especialyy adaptable to elderly patients.